Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

166.18
-0.0200-0.01%
Post-market: 166.190.0101+0.01%19:55 EDT
Volume:7.15M
Turnover:1.19B
Market Cap:42.64B
PE:-11.69
High:166.85
Open:166.55
Low:165.27
Close:166.20
52wk High:176.60
52wk Low:141.05
Shares:256.62M
Float Shares:256.62M
Volume Ratio:0.83
T/O Rate:2.79%
Dividend:2.45
Dividend Rate:1.47%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.24
PE(LYR):-11.69

Loading ...

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Resmed (RMD)

TIPRANKS
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Sunway Healthcare's Unit to Acquire Freehold Land in Related Party Deal

MT Newswires Live
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

FDA Approves Merck’s Welireg Plus Eisai’s Lenvima for Previously Treated Advanced Clear Cell Kidney Cancer

Reuters
·
Sep 25

Surrozen price target raised to $54 from $44 at H.C. Wainwright

TIPRANKS
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Sep 25

Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)

TIPRANKS
·
Sep 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Imunon (IMNN)

TIPRANKS
·
Sep 25

DRI Healthcare: Buy Rating Backed by Tavapadon Royalty Deal, Adding C$1.35 per Unit to Target Price and Enhancing Upside Potential

TIPRANKS
·
Sep 25

Xiayi Residents Urged to Check Expanded Social Insurance Subsidy Policy: Direct Payments to Individuals for Up to 12 Months

Deep News
·
Sep 25

Lanzhou to Stop Collecting Large Medical Insurance Premiums from Employers for Retirees Starting Next Year

Deep News
·
Sep 25